CGEM Nasdaq

Cullinan Management Inc

CGEM | $17.84 3.0% 2.91% 1.3M

(0.0% 1d) (11.7% 1m) (65.7% 1y) (0.0% 2d) (0.0% 3d) (3.9% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 768,291,107
https://www.cullinanoncology.com
Sec Filling | Patents | 24 employees

(US) Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

cancer ycombinator

add to watch list Paper trade email alert is off

Press-releases

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 0.7% | O: 15.52% H: 3.77% C: -12.83%
expansion therapeutics

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 0.7% | O: 15.52% H: 3.77% C: -12.83%
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| 2.6% | O: 2.98% H: 0.0% C: 0.0%
million therapeutics

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 2.0% | O: -1.12% H: 3.57% C: 0.71%
year update financial results

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
Published: 2024-03-01 (Crawled : 12:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| -6.23% | O: 3.41% H: 0.42% C: -3.09%
cln-619 fda drug clearance application

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-18 (Crawled : 22:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 89.7% | O: -0.33% H: 4.62% C: 0.88%
conference

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Published: 2023-12-14 (Crawled : 21:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 103.53% | O: 1.18% H: 2.56% C: -4.3%
cln-617 first protein trial il-12

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 75.66% | O: 0.2% H: 3.95% C: 0.61%
update financial results

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 84.26% | O: 2.13% H: 4.38% C: 3.33%

Cullinan Oncology to Participate in Upcoming Investor Conferences
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
CGEM | $17.84 3.0% 2.91% 1.3M

| 105.46% | O: 1.42% H: 2.34% C: 1.64%